ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Medpace Holdings Inc

Medpace Holdings Inc (MEDP)

402.99
7.04
(1.78%)
Closed June 18 4:00PM
402.99
-0.37
(-0.09%)
After Hours: 6:11PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
402.99
Bid
342.36
Ask
425.42
Volume
135,966
394.41 Day's Range 403.60
216.87 52 Week Range 421.00
Market Cap
Previous Close
395.95
Open
395.39
Last Trade
93
@
402.99
Last Trade Time
Financial Volume
$ 54,264,588
VWAP
399.1041
Average Volume (3m)
202,945
Shares Outstanding
30,759,281
Dividend Yield
-
PE Ratio
43.87
Earnings Per Share (EPS)
9.19
Revenue
1.89B
Net Profit
282.81M

About Medpace Holdings Inc

Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin Am... Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin America. Show more

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Medpace Holdings Inc is listed in the Coml Physical, Biologcl Resh sector of the NASDAQ with ticker MEDP. The last closing price for Medpace was $395.95. Over the last year, Medpace shares have traded in a share price range of $ 216.87 to $ 421.00.

Medpace currently has 30,759,281 shares outstanding. The market capitalization of Medpace is $12.41 billion. Medpace has a price to earnings ratio (PE ratio) of 43.87.

MEDP Latest News

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News

Apple (NASDAQ:AAPL) – Smartphone shipments from Apple in China fell 19% in the first quarter due to competition from Huawei. Its market share decreased to 15.7%, nearly matching that of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.61-0.64349112426405.6407.645386.425165744397.30582665CS
45.991.50881612091397410.05379.15165336394.81047214CS
12-2.24-0.552772499568405.23421355.79202945394.93826836CS
26103.1534.4016808965299.84421277.72224274373.78610983CS
52182.5582.8116494284220.44421216.87265023304.47166852CS
156223.42124.419446455179.57421126.945289656218.35294113CS
260345.48600.73030777357.5142157.385289338171.44973338CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CMTLComtech Telecommunications Corporation
$ 4.07
(87.56%)
91.42M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.33M
ASNSActelis Networks Inc
$ 2.11
(83.48%)
51.37M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.79M
LRHCLa Rosa Holdings Corporation
$ 1.78
(71.15%)
52.9M
STISolidion Technology Inc
$ 0.6881
(-64.35%)
16.36M
DMTKDermTech Inc
$ 0.1488
(-55.25%)
10.74M
QMCOQuantum Corporation
$ 0.3752
(-51.90%)
3.14M
ZNTLZentalis Pharmaceuticals Inc
$ 4.135
(-50.72%)
21.58M
AWINAERWINS Technologies Inc
$ 1.74
(-47.90%)
1.05M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.79M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.33M
NVDANVIDIA Corporation
$ 135.58
(3.51%)
294.3M
MBIOMustang Bio Inc
$ 0.8517
(13.56%)
291.93M
CRKNCrown Electrokinetics Corporation
$ 0.0548
(-17.10%)
92.39M

MEDP Discussion

View Posts
MiamiGent MiamiGent 1 year ago
Hi OJ, unfortunately I'm out of that issuse. I'm struggling with MCRB right now.
GL
MG
👍️ 1
OncoJock OncoJock 1 year ago
nice post

more, please

What do you make of this recent sale of roughly 30,000 shares of stock reported to the SEC by Stephen Ewald at Medpace Investors LLC?

Apparently the sale was timed to coincide with release of a good 1Q 2023 earnings report? They sold at around $221 per share, and the price has fallen to under $200 just a few days later.

Best wishes,

-- OJ
👍️0
OncoJock OncoJock 1 year ago
This forum needs some fresh posts.

I like this stock. I discovered it when I was researching publicly held contract research organizations. (This is related to my line of work as a medical writer specializing in oncology drug development.) Other CROs I discovered about the same time included Charles River Laboratories, Parexel, PPD, PRA Health Sciences, Syneos, Covance, and ICON. About the same time I also began to invest in laboratory supply houses including BioRad, Thermo-Fisher, Perkin-Elmer, and Danaher.

I first bought shares of MEDP in 2017, paying about $28 each. I've bought and sold a lot of shares since then. My current cost basis is $154 per share. At current prices, my stake in MEDP accounts for about 19% of my brokerage account, so I pay pretty close attention to ups and downs of the share price.

If anyone wishes to discuss the latest earnings report (which beat predictions on both earnings and revenue) I'd welcome the opportunity.

Cheers!

-- OJ
👍️0
MiamiGent MiamiGent 2 years ago
MEDP MEDPACE HOLDINGS INC
$214.51 +55.87 (+35.22%)
As of Oct-25-202210:10:18 AM ET

https://stockcharts.com/h-sc/ui?s=MEDP

Contract Research Organization Medpace Lifts FY22 Guidance, Highlights FY23 Outlook
By Benzinga — 7:29 AM ET 10/25/22
Medpace Holdings Inc's (NASDAQ:MEDP) Q3 revenue increased 29.8% Y/Y to $383.7 million, beating the consensus of $357.18 million, representing a backlog conversion rate of 17.7%.
On a constant currency organic basis, Q3 revenue was up 31.9%.
As of September 30, 2022, Backlog grew 20.9% to $2.2 billion. Net new business awards were $470.9 million, representing a net book-to-bill ratio of 1.23x.
Q3 EBITDA increased 48.5% to $89.3 million, or 23.3% of revenue, compared to $60.1 million, or 20.3% of revenue, a year ago.
Medpace posted an EPS of $2.05, up from $1.29 a year ago and beating the consensus of $1.47.
Financial Guidance: Medpace raised FY22 sales guidance to $1.44-$1.46 billion, versus the prior guidance of $1.405-$1.435 billion and the consensus of $1.41 billion.
EBITDA is expected to be $302-$310 million, versus the previous guidance of $268-$280 million
Medpace expects EPS of $6.88-$7.00 compared to prior guidance of $6.07-$6.36 and the consensus of $6.15.
For FY23, the company forecasts sales of $1.68-$1.74 billion, with EBITDA of $325-$350 million.
Price Action: MEDP shares traded higher by 28.13% at $203.26 in premarket on the last check Tuesday.

Company Profile
Sector Health Care
Industry Life Sciences Tools & Services
Company Location Cincinnati, OH

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
👍️ 1

Your Recent History

Delayed Upgrade Clock